Outcomes of Type 2 Diabetes Management: One Center Experience 2015–2023

Rudolf Chlup,Hana Zálešáková, Jiřina Gottwaldová, Michal Trefil,Jana Zapletalová, Richard Kaňa, Lada Hanáčková, Milena Bretšnajdrová, Přemysl Falt, Zdenka Polzerová

Type 2 Diabetes in 2024 - From Early Suspicion to Effective Management [Working Title](2024)

引用 0|浏览2
暂无评分
摘要
The purpose of this chapter was (1) to identify the frequency of employing different kinds of medication (beta-stimulators, metformin, gliflozins, incretins and/or insulins, pioglitazone, statins, fibrates), (2) to assess global metabolic effectiveness of this medication in a walk-in diabetes center, and (3) to estimate frequency of HbA1c measurements in people admitted to hospital. Methods: In 200 people with T2D (age 24–95 y, 105 men) HbA1c, BM, BMI, blood pressure [BP], lipoproteins HDL, LDL, TAG, eGFR, proteinuria were assessed. Individual observation periods took in the range of 0.5–8.8 years. Student’s t-test, Wilcoxon signed-rank test with Bonferroni correction and Spearman analysis were used to asses changes between the first and the last visit. P < 0.05 was considered as significant. In conclusion, reduction of HbA1c from start values of 52.6 (31.5–173.0) to 46.6 (31.5–116.6) mmol/mol along with reduction of BMI from 26.7 (16.0–45.3) to 25.4 (15.4–42.2) kg/m2 (P < 0.0001) and correlation of delta HbA1c with delta BMI (r = 0.209, p = 0.003) confirmed global metabolic effectiveness of medication used in the walk-in diabetes center where the HbA1c was estimated 2–3 times per year in each subject whereas in hospital wards mostly once in up to 15% of admitted T2D patients.
更多
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要